All News

Experts discuss the complexities of gene therapy for sickle cell disease, emphasizing patient support, psychosocial factors, and long-term care considerations.

New research reveals that effective bridging therapy before cilta-cel infusion significantly enhances safety and long-term outcomes in patients with multiple myeloma.

In an analysis of the intention-to-treat population of the BENEFIT study, investigators demonstrated improved sustained minimal residual disease negativity with the Isa-VRd regimen in newly diagnosed multiple myeloma (NDMM).

Experts at the ASH Annual Meeting and Exposition in Orlando, Florida, explored innovative strategies and treatments for improving outcomes in diffuse large B-cell lymphoma.

Project Optimus transforms cancer treatment by optimizing dosing strategies, enhancing efficacy, and reducing toxicities in modern therapies.

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

The American Society of Hematology (ASH) Annual Meeting and Exposition will feature the latest news, clinical trial updates, and key opinion leaders in the hematology field.

Key takeaways about unit-based pharmacy models for pharmacists and institutions.

Although highly efficacious, patient selection and adverse event management are crucial.

The Advisory Committee on Immunization Practices (ACIP) voted to recommend individual-based decision-making for parents when deciding when or if to give their child the birth dose of the hepatitis B virus vaccine.

Explore the rising use of phenobarbital in managing severe alcohol withdrawal syndrome, highlighting its benefits over traditional benzodiazepines in critical care.

Discover how the combination of palbociclib, trastuzumab, and endocrine therapy enhances survival in HER2-positive advanced breast cancer patients.

Shivang Joshi, MD, MPH, RPh, FAHS, highlights Symbravo’s non-substitutability, multi-mechanistic design, and key safety considerations for pharmacists across care settings.

Breyanzi becomes the first FDA-approved CAR-T therapy for relapsed marginal zone lymphoma, offering hope with impressive response rates and durable outcomes.

Expert pharmacists discuss future outlooks for unit-based pharmacy models.

MRD and ctDNA testing could revolutionize monitoring and diagnosing precursor diseases of multiple myeloma.

Continuous glucose monitoring (CGM) via interstitial fluid, sweat, and saliva are less invasive than prior methods.

Pharmacists discuss educational opportunities and training opportunities for pharmacists interested in unit-based pharmacy models.

Emerging pharmacy trends will be highlighted at the American Society of Health-System Pharmacists (ASHP) Midyear 2025, including AI innovations, GLP-1 therapies, and evolving geriatric and neonatal care.

The FDA approves a new dose of Omlyclo, the first interchangeable biosimilar to Xolair, enhancing treatment options for allergic and inflammatory conditions.

Research reveals low-dose cannabinoids, like THC, may enhance serotonin levels and combat chronic inflammation in patients with HIV, offering new treatment possibilities.

Researchers explore how immune history and innovative vaccine technologies enhance protection against flu, highlighting pharmacists' vital role in patient education.

Implementing a best practice advisory into physicians’ electronic health records improved lipid therapy initiation and diagnoses of hyperlipidemia and hypercholesterolemia.